GTX Genetix Grp

RNS Number:5205F
Genetix Group PLC
23 December 2002



                                 Board Appointment


New Milton UK, 23 December 2002 - Genetix, the UK-based supplier of automated
systems to the global genomics research industry, is pleased to announce the
appointment today of Peter Jensen as non-executive director. Mr Jensen, 52, has
extensive experience of the healthcare industry.

His early career with Johnson & Johnson and Sterling Health Products was
followed by a move in 1980 to Beecham Products International where he held a
number of senior positions including Managing Director Health & Personal Care UK
SmithKline Beecham (1986-1992).

From 1992 to 1998, Mr Jensen was Chairman of SmithKlineBeecham's European
Consumer Healthcare operations before being appointed President of the company's
Worldwide Supply Operations. Following the formation of GlaxoSmithKline, Mr
Jensen was a member of the GSK Integration Planning Committee.

Mr Jensen is currently Chairman of the European Business Forum, a non-executive
director of Domino Printing Sciences plc and a non-executive of Newmarket
Racecourses Trust. He is also a Fellow of The Marketing Society.

Mark Reid, CEO of Genetix, said: "We are very pleased to welcome Peter to the
Board.  His immense experience in marketing will help Genetix to continue to
develop its broadening product range."

In accordance with paragraph 16.4 of the UKLA's Listing Rules, Mr Jensen is
currently a director of Domino Printing Sciences plc.

There are no other disclosures required under paragraph 6.F.2 (b)-(g).


Genetix Group plc

Mark Reid, Chief Executive Officer                     Tel:  +44 (0) 1425 624600
Gary Corsi, Finance Director

Financial Dynamics
Ben Atwell                                               Tel:  +44 (0) 7831 3113


Notes to Editors

Genetix Group plc

Genetix Group plc provides automated systems and services for genomic and
proteomic research. It supplies many leading academic institutions world-wide
including the Max Planck Institute and major international companies involved in
the drug discovery process including GSK, AstraZeneca and Novartis.

Genetix made a significant contribution to the Human Genome Project by supplying
high-throughput equipment to seven of the leading eight laboratories of the
consortia. Genetix through its R&D expertise and scientific resource is
committed to the continual development of innovative solutions to accelerate the
rate of global scientific discovery. Genetix is quoted on the London Stock
Exchange and is based in New Milton, Hampshire, UK.  www.genetix.com


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END
BOAZXLFLLLBBFBZ

Genetix Grp (LSE:GTX)
Historical Stock Chart
From Jun 2024 to Jul 2024

Genetix Grp (LSE:GTX)
Historical Stock Chart
From Jul 2023 to Jul 2024